Online inquiry

IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12135MR)

This product GTTS-WQ12135MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD248 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_020404.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57124
UniProt ID Q9HCU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12135MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1850MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ4250MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ12672MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ10063MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ2079MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ12878MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ1993MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGS-22CE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW